Objective-MicroRNAs (miRs) play important regulatory roles in lipid metabolism. Apolipoprotein B (ApoB), as the only essential scaffolding protein in the assembly of very-low-density lipoproteins, is a target to treat hyperlipidemia and atherosclerosis. We aimed to find out miRs that reduce apoB expression. Approach and Results-Bioinformatic analyses predicted that hsa-miR-548p can interact with apoB mRNA. MiR-548p or control miR was transfected in human and mouse liver cells to test its role in regulating apoB secretion and mRNA expression levels. Site-directed mutagenesis was used to identify the interacting site of miR-548p in human apoB 3′-untranslated region. Fatty acid oxidation and lipid syntheses were examined in miR-548p overexpressing cells to investigate its function in lipid metabolism. We observed that miR-548p significantly reduces apoB secretion from human hepatoma cells and primary hepatocytes. Mechanistic studies showed that miR-548p interacts with the 3′-untranslated region of human apoB mRNA to enhance post-transcriptional degradation. Bioinformatic algorithms suggested 2 potential binding sites of miR548p on human apoB mRNA. Site-directed mutagenesis studies revealed that miR-548p targets site I involving both seed and supplementary sequences. MiR-548p had no effect on fatty acid oxidation but significantly decreased lipid synthesis in human hepatoma cells by reducing HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) and ACSL4 (Acyl-CoA synthetase long-chain family member 4) enzymes involved in cholesterol and fatty acid synthesis. In summary, miR-548p reduces lipoprotein production and lipid synthesis by reducing expression of different genes in human liver cells. Conclusions-These studies suggest that miR-548p regulates apoB secretion by targeting mRNA. It is likely that it could be useful in treating atherosclerosis, hyperlipidemia, and hepatosteatosis. Visual Overview-An online visual overview is available for this article. 
M icroRNAs (miRs) are small endogenous noncoding RNAs. Since 1993, when the first miR was identified and cloned from Caenorhabditis elegans, 1 the regulatory functions of miRs have been studied extensively in different species. 2 Furthermore, significant attempts have been made to test the potential use of miRs as therapeutic agents. MiR-122, the most abundant miR expressed in the liver, binds to the 5′-untranslated region (5′-UTR) of the hepatitis C virus genome to positively affect RNA stability and replication. 3 Therefore, inhibition of endogenous miR-122 shows efficacy in treating chronic hepatitis C infection. And, a locked nucleic acid-modified anti-miR-122, miraversin, is in phase II clinical trials. [4] [5] [6] MiR-34, which is induced by a tumor suppressor p53, reduces the expression of multiple genes in apoptosis and cell cycle arrest to suppress tumor genesis. 7, 8 MRX34, a doublestranded miR-34 mimic, has been shown to enhance cancer cell death and inhibit metastasis in a phase I clinical trial. 9 These promising results from preclinical and clinical studies encourage us to seek for miRs that can potentially treat cardiovascular diseases that remain the major cause of morbidity and mortality in the Western world. 10 Atherosclerosis, the major cause of cardiovascular diseases, occurs because of excess lipid accumulation on the inner wall of arteries. 11 Atherosclerotic lesions in major arteries narrow their diameters and reduce blood circulation. 12 Several risk factors of atherosclerosis have been identified, such as hyperlipidemia, hypertension, smoking, lack of exercise, and family history. Hyperlipidemia refers to increases in plasma lipids and lipoproteins. High plasma concentrations of low-density lipoproteins (LDLs) and their modified forms, such as oxidized LDL, contribute to atherosclerosis. And, lowering their concentrations is associated with reduced incidence of cardiovascular disease.
reduce plasma LDL by increasing their clearance via upregulating hepatic LDL receptors. 15, 16 Hence, these drugs are not useful in the treatment of homozygous familial hypercholesterolemia subjects with null LDL receptor mutations. 17, 18 Hypercholesterolemia in these patients can be lowered using drugs that decrease apolipoprotein B (apoB) or microsomal triglyceride transfer protein (MTP); 2 critical proteins required for the assembly and secretion of very-low-density lipoprotein. 17, 19, 20 During very-low-density lipoprotein assembly, newly translated apoB peptides are lipidated in the endoplasmic reticulum (ER) by MTP. [19] [20] [21] ApoB siRNAs and antisense oligonucleotides (ASOs) reduce lipoprotein production and plasma cholesterol in both rodents and nonhuman primates. [22] [23] [24] [25] Mipomersen, a specific apoB ASO, has been approved to treat homozygous familial hypercholesterolemia. 17, 19 Mipomersen reduces plasma cholesterol but is associated with lipid accumulation in the liver. 17, 19, [26] [27] [28] [29] Similarly, small molecule inhibitors and ASO-mediated reductions in MTP lower plasma cholesterol but are also associated with increases in hepatic lipids. 19, 20, [30] [31] [32] Therefore, novel therapeutic agents that reduce very-low-density lipoprotein production while avoiding hepatosteatosis might be useful treatment modalities.
Few miRs have been reported to regulate metabolism of apoB-containing lipoproteins. 33, 34 Inhibition of miR-122 results in significant reductions in plasma cholesterol, apoB, and triglyceride. [35] [36] [37] Furthermore, miR-122 knockout mice have lower plasma cholesterol and triglyceride because of reductions in both LDL and high-density lipoprotein. These mice have higher hepatic lipids and plasma alanine aminotransferase and alkaline phosphatase and develop hepatocellular carcinoma with age. 38, 39 MiR-34a expression reduces lipoprotein production and causes hepatosteatosis. 40 
Mir34a
−/− mice have high plasma triglyceride and cholesterol. 40 Recently, we showed that miR-30c reduces MTP expression and lowers plasma cholesterol and atherosclerosis without causing steatosis. 41, 42 Mechanistic studies indicated that miR-30c reduces lipoprotein production and lipid synthesis. Moreover, miR33a/b was identified for its role in downregulating ABCA1 (ATP-binding cassette subfamily A member 1) in macrophages to inhibit cholesterol efflux and high-density lipoprotein biosynthesis. [43] [44] [45] Here, we investigated whether there are miRs that target apoB to regulate lipoprotein production and identified a novel human miR-548p, which targets apoB mRNA, that decreases apoB secretion and reduces hepatic lipid synthesis in human hepatoma cells.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MiR-548p Lowers ApoB Secretion From Human Liver Cells
Using TargetScan 5.2, we observed that human apoB mRNA has a target site for hsa-miR-548p ( Figure I in the onlineonly Data Supplement) that is conserved in primates but not in other organisms, including dog, mouse, rat, chicken, and frog ( Figure 1A ). To test whether hsa-miR-548p affects human apoB secretion, different indicated concentrations of control miR, miR-548p, and anti-548p were transfected in Huh-7 cells ( Figure 1B) . MiR-548p dose-dependently reduced media and cellular apoB without changing apoAI levels ( Figure 1B ). Anti548p, an inhibitor of miR-548p, increased both media and cellular apoB without affecting apoAI secretion, indicating the role of endogenous miR-548p in apoB regulation ( Figure 1B) . Further studies showed that miR-548p reduces media and cellular apoB in a time-dependent manner ( Figure 1C ). The maximum reduction of 67% was observed after 72 hours. Anti-548p increased media and cellular apoB levels without affecting apoAI ( Figure 1C ). In addition, we observed the same effect of miR-548p on apoB in another human hepatoma cell line, HepG2 ( Figure 1D ). Forced expression of miR548p reduced media and cellular apoB, but had no effect on apoAI ( Figure 1D ). However, anti-548p increased media and cellular apoB. We also tested the effect of miR-548p on apoB and apoAI secretion in human primary hepatocytes compared with negative control. MiR-30c was used as a positive control of transfection efficiency, as it is known to target MTP and reduce apoB secretion. 41, 42 MiR-548p significantly reduced apoB secretion from the primary hepatocytes without affecting apoAI ( Figure 1E ). Thus, miR-548p reduces cellular and media apoB in human liver cells without altering apoAI levels.
MiR-548p Reduces ApoB mRNA Levels in Human, But Not in Mouse, Liver Cells
To begin to understand how miR-548p regulates apoB secretion, we quantified apoB, MTP, and apoAI mRNA levels in miR-548p, miR-30c, and control transfected human primary hepatocytes. MiR-548p significantly reduced apoB mRNA levels without affecting MTP or apoAI, whereas miR-30c only reduced MTP mRNA levels ( Figure 2A ). In Huh-7 cells, miR-548p reduced and anti-548p increased apoB mRNA levels. MiR-548p and anti-548 had no effect on MTP and apoAI mRNA levels ( Figure 2B ). These studies indicate that miR548p reduces steady-state apoB mRNA levels in liver cells.
Because mouse is the most widely used animal model to study physiological effects of genetic manipulations and drug treatments, we transfected miR-548p in mouse primary hepatocytes ( Figure 2C ) and in mouse hepatoma AML12 cells ( Figure 2D ). MiR-548p and anti-548p had no effect on mouse apoB, MTP, or apoAI. This is consistent with the absence of miR548p-interacting site in the 3′-UTR of mouse apoB ( Figure 1A ). Thus, miR-548p reduces apoB mRNA levels in human liver cells.
MiR-548p Interacts With the 3′-UTR of ApoB to Induce Post-Transcriptional Degradation
MiRs, in general, reduce mRNA levels by interacting with 3′-UTR of mRNAs and inducing post-transcriptional Therefore, we hypothesize that miR-548p may induce post-transcriptional degradation of apoB mRNA. ApoB mRNA disappeared faster in miR-548p expressing cells than in control transfected cells treated with actinomycin D to inhibit transcription ( Figure 3A) . Hence, miR-548p promotes post-transcriptional degradation of apoB mRNA.
To identify interactions between miR-548p and apoB mRNA, we cloned wild-type 3′-UTR of apoB mRNA at the end of luciferase cDNA in psiCHECK plasmid ( Figure 3B ) and expressed in Huh-7 cells. Compared with the control, miR-548p reduced and anti-548p increased luciferase activity in cells transfected with luciferase containing wild-type apoB 3′-UTR ( Figure 3C ). These studies suggest that miR-548p interacts with 3′-UTR of apoB.
Both Seed and Supplementary Sites in miR-548p
Interact With the 3′-UTR of ApoB mRNA at Site II Attempts were then made to identify miR-548p-interacting site in the apoB mRNA. miRanda predicted that human apoB 3′-UTR contains 2 potential target sites for miR-548p ( Figure 3D ). Both sites contain perfect complementary binding sites for miR-548p seed sequence and also contain possible interaction sites involving supplementary sequences. To determine whether miR-548p interacts with these sequences, we mutated these sites to perturb potential base pairing ( Figure 3D ). Mutations in either seed or supplementary sequences in site I resulted in loss of miR-548p effect on luciferase activity ( Figure 3E ). However, mutations of site II seed and supplementary sequences did not affect luciferase activity ( Figure 3E ). These studies suggest that miR-548p interacts with the 3′-UTR of apoB by interacting with both seed and supplementary sequences at site I.
MiR-548p Decreases Hepatic Lipid Synthesis
Inhibition of apoB secretion is usually associated with cellular lipid accumulation. 47 Therefore, we asked whether miR-548p would increase cellular lipids. No significant differences were observed in total cellular triglyceride and cholesterol levels in cells transfected with control and miR-548p ( Figure 4A and  4B) . Thus, miR-548p expression does not cause lipid accumulation in Huh-7 cells. MicroRNA (MiR)-548p decreases cellular and secreted apolipoprotein B (apoB) from human liver cells without affecting apoAI secretion. A, TargetScan 6.2 was used to predict putative miRs that could target apoB 3′-untranslated region. The miR-548p seed sequence-interacting site in apoB mRNA is well conserved in primates, including human, chimpanzee, and rhesus monkeys, but not in mouse and rat. B, Different amounts of control (Ctrl), miR-548p, and anti-548p (100 nmol/L) were reverse transfected in Huh-7 cells. Cellular apoB, as well as media apoB and apoAI, were quantified using ELISA 48 h after transfection. The data are representative of 2 independent experiments. C, Time course experiments in Ctrl, miR-548p, and anti-548p (100 nmol/L) transfected Huh-7 cells. Media and cell lysates were collected at indicate time points to measure secreted and cellular apoB and apoAI. D, MiR-548p (100 nmol/L) decreased apoB secretion in HepG2 cells without affecting apoAI. ApoB and apoAI in cells and media were measured 48 h after transfection. The data are representative of 2 independent experiments. E, MiR-548p and miR-30c (100 nmol/L) decreased apoB secretion in human primary hepatocytes without affecting apoAI. *P<0.05, **P<0.01, ***P<0.001. Significance was calculated by 2-way ANOVA and Student t test.
To explain reasons for the absence of lipid accumulation in miR-548p expressing cells, we examined the effects of miR548p on fatty acid oxidation and lipid synthesis ( Figure 4C and 4D). Fatty acid oxidation was unaffected ( Figure 4C ). However, miR-548p significantly decreased cholesterol, fatty acid, and triglyceride synthesis by 20%, 30%, and 33%, respectively, but had no effect on phospholipid synthesis ( Figure 4D ). These studies indicate that miR-548p decreases lipid synthesis.
To explain how miR-548p decreases cholesterol and fatty acid synthesis, we measured mRNA levels of genes involved in lipid synthesis that are predicted to contain potential target sites of miR-548p ( Figure 4E ). HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) and ACSL4 (Acyl-CoA synthetase long-chain family member 4) mRNA levels were significantly reduced in miR-548p expressing cells. However, mRNA levels of other enzymes involved in triglyceride and fatty acid biosynthesis, as well as fatty acid oxidation, were not affected ( Figure 4E ). Furthermore, cellular proteins levels of these enzymes were significantly reduced ( Figure 4F ) in miR-548p expressing cells, whereas GAPDH protein levels were unaffected. Furthermore, media apoE and PCSK9 levels were unaffected by miR-548p expression. HMGCR is a ratelimiting enzyme in cholesterol synthesis. 48 ACSL4 plays a role in fatty acid and triglyceride synthesis. 49, 50 Thus, miR-548p may target HMGCR and ACSL4 to reduce lipid synthesis.
To determine whether miR-548p directly regulates ACSL4, we used luciferase constructs containing the 3′-UTRs of ACSL4. MiR-548p overexpression significantly decreased the luciferase activity when it was expressed with the ACSL4 3′-UTR, indicating a direct interaction between ACSL4 3′-UTR and miR-548p ( Figure 4G ).
Discussion
Here, we report identification of a novel miR, miR-548p, that targets apoB mRNA and reduces intracellular and media apoB levels. MiR-548p interacts with the 3′-UTR of apoB mRNA involving both seed and supplementary sequences at site I. These interactions induce post-transcriptional degradation of mRNA and reduce secretion of apoB from human liver cells. In addition, we observed that miR-548p significantly reduces lipid synthesis. This is most likely because of diminished expression of ACSL4 and HMGCR, 2 enzymes involved in fatty acid and cholesterol biosynthesis. Thus, miR-548p reduces lipid synthesis and lipoprotein production via independent mechanisms targeting different mRNAs.
The importance of interactions between apoB mRNA and miR-548p in the regulation of apoB secretion is supported by several experiments. Bioinformatic analyses predict conserved interacting sites in primates. Cloning of 3′-UTR of apoB mRNA at the end of luciferase renders luciferase susceptible to miR-548p-dependent regulation. Mutagenesis of 3′-UTR sequence abolishes the regulation by miR-548p. Mouse apoB is not regulated by miR-548p most likely because of the absence of miR-548p-interacting site.
According to miRanda, human apoB 3′-UTR contains 2 targeting sites for miR-548p involving perfect seed sequence Watson-Crick base pair interactions. In contrast, TargetScan predicts only 1 site that corresponds to the site II predicted by miRanda. Site-directed mutagenesis studies revealed that only 1 predicted site, site I, contributes to the regulation of apoB mRNA ( Figure 3 ). This is consistent with the general understanding that the first miR-interacting site after the stop codon is important for physiological activity. However, this interaction starts with the residue 3 of the miR-548p. Usually, residue MicroRNA (MiR)-548p reduces apolipoprotein B (apoB) mRNA levels in human primary hepatocytes and Huh-7 cells. A, In the human primary hepatocytes, miR-548p (100 nmol/L) reduced apoB mRNA levels and miR-30c (100 nmol/L) reduced microsomal triglyceride transfer protein (MTP) mRNA levels. B, MiR-548p and anti-miR-548p (100 nmol/L) decreased and increased apoB mRNA levels, respectively, in Huh-7 cells. The data are representative of 2 independent experiments. C, MiR-548p or anti-miR-548p (100 nmol/L) has no effect on mouse apoB in mouse primary hepatocytes. D, MiR-548p (100 nmol/L) has no effect on mouse apoB in AML12 cells. The data are representative of 2 independent experiments. The mRNA expression levels of apoB, MTP, or apoAI were quantified after 48 h of transfection. Relative mRNA levels were normalized to 18S. *P<0.05, ***P<0.001. Significance was calculated by Student t test. Ctrl indicates control.
2 of miR is involved in the first H-bonding with mRNAs. In fact, the predicted binding of miR-548p at site II starts with the second residue. It is likely that this site is not available for miR-548p as the binding start site is ≈ 12 nucleotides away from the end of the first binding site. Thus, if the site I is occupied by a RISC (RNA-induced silencing complex) complex, then the site II may not be accessible for additional interactions. At this site I, both seed and supplementary site interactions seem important for miR-548p to regulate apoB mRNA levels as mutagenesis of residues involved in these site interactions abolish response to miR-548p. A previous study about the interaction of miR-30c and MTP has highlighted the importance of supplementary site interactions. 51 Therefore, it is likely that miR-548p interacts with the first possible interaction site available after the stop codon, and these interactions involve both seed and supplementary sequences.
MiR-548p is a member of a large primate-specific family. 52 Most of the miRs are conserved in different species. 42, 53, 54 The conservation allows an easy way to evaluate physiological effects of overexpression or loss-of-function of specific miRs in model organisms before human studies. Nevertheless, many human or primate-specific miRs have been identified that play important roles in physiological and pathological pathways, such as cellular differentiation and cancer development. [55] [56] [57] It is likely that primate miRs have evolved to regulate species-specific phenotypes. Primates carry most of the cholesterol in LDL, whereas mice carry it in high-density lipoprotein. Consistent with this, 3′-UTR of primate apoB mRNA contains miR-548p targets sites that carry cholesterol mainly in LDL ( Figure 1A) . And, this interacting site is not present in animals that carry cholesterol mainly in high-density lipoprotein, such as mouse. Thus, miR-548p might have evolved to regulate plasma LDL levels.
MiR-548p is predicted to be transcribed from an independent gene (MIR548P) that is present on the opposite strand of the ST8 α-N-acetyl-neuraminide α-2, 8-sialyltransferase 4 (ST8SIA4) gene ( Figure IIA in the online-only Data Supplement) that encodes an enzyme required for the synthesis of polysialic acid. 58 MiRs are known to be transcribed as pri-miR, to undergo cleavage, and to be transported across the nucleus as pre-miR. Not only the mature miR but also the premiR548p is conserved in primates ( Figure IIB in the A, Huh-7 cells were transfected with control (Ctrl) or miR-548p (100 nmol/L). After 24 h, cells were incubated with actinomycin D (1 μg/mL, from 1 mg/mL stock). ApoB mRNA levels at different time points were normalized using 18S as internal control. The apoB mRNA levels relative to time point 0 were plotted. B, ApoB 3′-UTR was amplified from genomic DNA by polymerase chain reaction (PCR) and cloned into psiCHECK2 vector at the end of Renilla luciferase cDNA. C, Plasmids (1.5 µg) containing human apoB 3′-UTR were transfected in Huh-7 cells using transfection reagent TurboFect (Life Technologies). After 24 h, Ctrl, miR-548p, and anti-548p (100 nmol/L) were introduced into cells. After 48 h, dual luciferase activities were assayed. The data are representative of 2 independent experiments. D, Two potential targeting sites (site I and site II) were predicted by miRanda. ApoB 3′-UTR has complementary bases that could interact with both seed and supplementary sequences. Every seed and supplementary sequence was mutated using site-directed mutagenesis. E, Luciferase reporter plasmids (1.5 μg) containing wild-type or different mutant human apoB 3′-UTR were transfected in Huh-7 cells. Cells were then transfected with Scr or miR-548p (100 nmol/L). Luciferase activity was measured after 24 h. The data are representative of 2 independent experiments. *P<0.05, **P<0.01, ***P<0.001. Significance was calculated by 2-way ANOVA and Student t test.
online-only Data Supplement). It has been reported that miR-548p is present in several human tissues, including blood, brain, liver, lung ( Figure III in the online-only Data Supplement).
To our knowledge, miR-548p is the first miR that has been shown to target apoB mRNA and decrease apoB secretion from human hepatoma cells. MTP and apoB are the 2 critical proteins in apoB-containing lipoprotein assembly and secretion. Inhibition of MTP causes hepatosteatosis and elevates plasma AST and alanine aminotransferase activities. In the absence of MTP, lipids are not transferred from ER membrane to ER lumen. Therefore, the newly synthesized lipids, mainly triglyceride, are stored in cytosolic lipid droplets. However, when apoB expression is reduced, lipids can still be transferred to ER lumen by MTP. Lipid accumulation in the ER lumen has been shown to activate autophagy, which engulfs and hydrolyzes lipids in lysosomes. 25 Fatty acids generated from lipolysis are then oxidized in mitochondria. Therefore, in mice treated with apoB ASOs, hepatic triglyceride levels increase soon after injection (first 3 weeks) and later resolve because of higher fatty acid oxidation. 25 Hence, targeting apoB might be an appropriate way to reduce very-low-density lipoprotein production. In this study, we show that miR-548p reduces apoB mRNA to decrease apoB protein secretion from human hepatocytes and Huh-7 and HepG2cells ( Figure 1 ) and also lowers hepatic cholesterol and fatty acid synthesis by suppressing the expression of HMGCR and ACSL4 (Figure 4 ). Thus, it is possible that early steatosis seen with apoB ASO can be avoided by miR-548p overexpression and may be evaluated in the future in primates.
With this report, we have now identified 2 miRs that seem to have similar physiological regulatory effects. MiR-30c reduces lipoprotein production by targeting MTP and lipid synthesis by targeting ELOVL5 (ELOVL fatty acid elongase 5) A and B, Overexpression of miR-548p had no effect on cellular lipid levels. Cellular triglyceride and cholesterol were extracted and quantified in control (Ctrl) or miR-548p (100 nmol/L) transfected Huh-7 cells. C and D, MiR-548p (100 nmol/L) reduced cholesterol and triglyceride synthesis without affecting fatty acid oxidation in Huh-7 cells. CE indicates cholesteryl ester; FA, fatty acid; PL, phospholipid; and TG, triglyceride. The data are representative of 3 independent experiments. E, Genes in lipoprotein assembly, triglyceride, cholesterol, and fatty acid biosynthesis were quantified using quantitative reverse transcription-polymerase chain reaction. The data are representative of 3 independent experiments. F, Western blots of GAPDH, ACSL4 (Acyl-CoA synthetase long-chain family member 4), and HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) in Ctrl or miR-548p (100 nmol/L) transfected Huh-7 cells (left). Medium from transfected cells was used to immunoprecipitate apoE and PCSK9 (proprotein convertase subtilisin/kexin type 9) and then subjected to Western blotting (left). Specific protein bands were quantified using ImageJ and plotted as bar graphs (right). G, Luciferase reporter plasmids (1.5 μg) containing human ACSL4 or HMBCR 3′-untranslated regions (3′-UTRs) were transfected in Huh-7 cells. Cells were then distributed in different wells and transfected with Ctrl or miR-548p (100 nmol/L). Luciferase activity was measured after 24 h. *P<0.05, **P<0.01, ***P<0.001. Significance was calculated by Student t test. The data are representative of 2 independent experiments. and LPGAT1 (Acyl-CoA:lysophosphatidylglycerol acyltransferase 1). 41, 42 MiR-548p reduces lipoprotein production by targeting apoB and lipid synthesis by lowering ACSL4 and HMGCR. To our knowledge, this is the first report describing 2 different miRs affecting the same physiological processes by targeting different genes. It is likely that nature has evolved multiple miRs to regulate similar pathways because of their physiological importance. Alternatively, the evolution of different miRs may represent redundant mechanisms for their regulation.
From genetic and therapeutic studies, it is well-known that separate inhibition of lipoprotein synthesis and lipid synthesis results in different diseases. For example, defects in lipoprotein production result in hypolipidemia that is associated with accumulation of lipids in tissues. 19 However, defects in lipid synthesis are associated with lipodystrophy. 59 In contrast, combined reduction of both these metabolic pathways seems to avoid pathologies associated with defects in individual pathways. Therefore, targeting of multiple related pathways might be more beneficial than the classical approach of targeting individual proteins/pathways.
Although these studies advocate for the identification and use of miRs that affect multiple pathways with beneficial outcomes, these approaches need extensive evaluation. A major concern about miR therapies is unanticipated effects. Hence, a rigorous evaluation of all anticipated and unanticipated effects is warranted before advocating their use in humans.
In short, these studies have identified miR-548p that reduces expression of apoB, HMGCR, and ACSL4 to diminish lipoprotein production and lipid synthesis. Because of its ability to control these 2 pathways, similar to miR-30c, it might reduce plasma cholesterol and atherosclerosis without causing steatosis. However, this can only be evaluated in primates. Such studies will provide strong evidence for further clinical investigations in humans.
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